BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

BioMarin (BMRN) and Ascendis resolved global patent disputes over Yuviwel, including dismissing a pending U.S. ITC Section 337 investigation. Ascendis will pay BioMarin royalties of 20% of Yuviwel net sales in the U.S. (retroactive to the first commercial sale) and 18% of net sales in the EU, Brazil, and South Korea until May 2030, with a license covering BioMarin patents for Yuviwel across current and potential indications.

Analysis

This is a cleaner outcome for BMRN than for ASND. The economic read-through is not the headline royalty rate itself, but the fact that BioMarin has effectively converted IP friction into a toll-booth on a competing CNP asset while preserving the exclusivity halo around its own franchise. That matters because rare-disease investors pay up for durable cash flow visibility; a validated IP perimeter can support multiple expansion for BMRN if the market starts to believe the franchise is harder to displace than previously modeled.

For ASND, the overhang is removed, but the price is a permanent tax on operating leverage in a product that likely needs high gross-to-net efficiency to justify launch economics. The near-term reaction can still be positive because injunction risk is gone, yet over 6-18 months the settlement cap on margins may force a lower terminal profit pool than bulls were underwriting. Second-order, this also raises the bar for any would-be CNP competitors: rather than a clean race to market, the category now looks more like a licensed duopoly with BioMarin capturing economics even where it is not the commercial seller.

The key risk is that investors overestimate the cash impact before there is visible sell-through. If Yuviwel sales ramp slowly, BMRN’s royalty stream is immaterial and the settlement becomes mostly symbolic; if launch momentum is strong, the stream could become a meaningful incremental annuity. Contrarian view: ASND may be the better short only after an initial relief rally, because the market could ignore that a 20% U.S. royalty is materially dilutive to peak operating margin assumptions.

Key Decisions for Investors

• Long BMRN vs short ASND as a relative-value pair over 1-3 months: thesis is asymmetric benefit from royalty capture and IP-strength signaling at BMRN versus capped economics for ASND. Falsify if BMRN guidance does not mention any monetization or if ASND launch commentary shows stronger-than-expected pricing/volume.
• Buy BMRN on any post-news pullback rather than chasing the first move; the better setup is a multi-month multiple re-rating if investors conclude the VOXZOGO/CNP moat is more durable. Risk/reward improves if BMRN trades back to pre-gap levels while litigation uncertainty is still fully removed.
• Fade ASND strength only if the stock rallies into the settlement and valuation implies unencumbered peak margins. Use a tactical short or put spread, with the thesis breaking if Yuviwel demand inflects quickly enough to offset the royalty drag.
• Watch for 2-3 month launch data or management commentary on Yuviwel uptake; if sales are weak, the settlement is mostly noise and both names should drift back toward fundamentals. If sales surprise to the upside, BMRN’s royalty could become a small but durable earnings kicker.